DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

It’s easy to forget to drink water during the day, but dehydration can often be the culprit behind that nagging headache. Just a simple glass of water could do wonders. Staying hydrated ...

Anyone who experiences migraines knows they extend far beyond “just a headache.” The throbbing pain, often concentrated on one side of the head, frequently arrives with nausea, vomiting ...

The pain message travels along the trigeminal nerve, which is responsible for the feeling in your face and head. The brain gets suddenly confused, and thinks the pain is coming from your forehead ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

In separate filings made in the U.S. Bankruptcy Court for the District of Maryland this week, the future of Diamond Comic Distributors grew murkier and more fraught. The first motion was made ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd, announced that the U.S.

A Kentucky lawmaker is urging the federal government to delay its forthcoming REAL ID deadline as his state and others face a whirlwind of logistical issues. "Kentucky wants to comply with REAL ID ...

Following a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, ...

But the Swedish automaker’s newly reinstated chief executive officer still has plenty of other headaches to manage.